Filing Details

Accession Number:
0001567619-22-001225
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-01-14 20:45:51
Reporting Period:
2021-12-21
Accepted Time:
2022-01-14 20:45:51
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1048477 Biomarin Pharmaceutical Inc BMRN Pharmaceutical Preparations (2834) 680397820
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1221590 Jacques Jean Bienaime C/o Biomarin Pharmaceutical Inc.
770 Lindaro St.
San Rafael CA 94901
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-12-21 100 $89.22 303,789 No 4 L Direct
Common Stock Acquisiton 2022-01-12 5,000 $37.46 308,789 No 4 M Direct
Common Stock Disposition 2022-01-12 5,000 $89.00 303,789 No 4 S Direct
Common Stock Acquisiton 2022-01-13 5,000 $37.46 308,789 No 4 M Direct
Common Stock Disposition 2022-01-13 5,000 $87.86 303,789 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 L Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to buy Common Stock) Disposition 2022-01-12 5,000 $0.00 5,000 $37.46
Common Stock Stock Option (Right to buy Common Stock) Disposition 2022-01-13 5,000 $0.00 5,000 $37.46
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
120,000 2012-11-08 2022-05-07 No 4 M Direct
115,000 2012-11-08 2022-05-07 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 247,533 Indirect Shares held by Jean-Jacques Bienaime Family Trust
Footnotes
  1. Trade made pursuant to a 10b5-1 plan executed on October 13, 2021.
  2. The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 50 shares, with the reporting person's purchase of shares at a price of $78.7700 on September 9, 2021. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs.
  3. Reflects the number of options outstanding after the transactions from this specific stock option grant.